More importantly, the tumor-suppressive activity of Casein kinase II inhibition on YAP1 stability and YAP1-dependent malignant processes were also observed in cancer cell lines of pancreatic ductal adenocarcinoma (PDAC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and hepatocellular carcinoma (HCC). This evidence concerns the gene YAP1 and cancer.